DEX LMANCT07562308
Laryngeal Mask Airways Are Supraglottic Devices Used to Maintain Airway Patency During Anesthesia and in Difficult Airways. IV Dexmedetomidine Improves LMA Insertion Success and Decreases Coughing, While IV Lidocaine Decreases Postoperative Cough.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria shortened, about 17 words Show 5 more changesShow less
- Completed without a posted recruiting period
- Study completion date changed from estimate of Sep 30, 2026 to Nov 1, 2026
- Study sites: 1 to 2
- Secondary endpoints: details revised at 5 of 8 entries
- Publications: details revised at 3 of 3 entries
- Notable Start date: Apr 1, 2026 to May 1, 2026
- Eligibility criteria revised
- Primary completion pushed from Jul 1, 2026 to Aug 1, 2026
- Study completion pushed from Aug 30, 2026 to Sep 30, 2026
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
First-attempt insertion success rate
Timeframe: After induction of anesthesia
Secondary (8)
Ease of insertion (4-point scale)
Heart rate
MAP
Recovery Time
Postoperative Agitation
Show 3 moreShow less
Postoperative Complications
PONV
Postoperative sore throat (0-3 scale).
Arms and interventions
Group (D) DEXActive comparator
Dose: 0.2 mcg/kg IV in 10 mL saline, infused over 10 min pre-induction.
Group (L) LidocaineActive comparator
Dose: 1.5 mg/kg IV (max 100 mg) in 10 ml saline over 1 min before induction.
Drugs: Dexamedomedine, Lidocaine (drug)
Sites
2 sites in 1 country